Single Infusion of Gene-Editing Therapy VERVE-102 Shows Promise for Inherited High Cholesterol
By
Anastasia Scott
1d ago· 4 min readenNews
85/100
Golden Brown
Bagelometer↗
Toasted golden, schmeared with insight. Top of the rack.
Score85TypenewsSentimentpositive
Summary
An experimental gene-editing therapy called VERVE-102, developed by Verve Therapeutics (a subsidiary of Eli Lilly), shows promise in treating familial hypercholesterolaemia — an inherited condition causing dangerously high cholesterol from birth. Early clinical trial results published in the New England Journal of Medicine indicate that a single infusion of the therapy can lower harmful cholesterol levels, potentially replacing the lifelong daily regimen of pills and injections that patients currently must follow.
Key quotes
· 4 pulledFor people born with familial hypercholesterolaemia, an inherited condition that causes dangerously high cholesterol from birth, managing it isn't a lifestyle choice.
It's a daily obligation: pills every morning, injections every few weeks, a regimen that begins young and, for most, never ends.
A new experimental therapy aims to change that with one infusion.
Results from an early clinical trial, published in the New England Journal of Medicine, show that one dose of VERVE-102, a gene-editing therapy developed by Verve Therapeutics, a subsidiary of Eli Lilly, can lower harmful cholesterol in patients.
Learn how gene editing may help people born with dangerously high cholesterol lower their levels with just one infusion.
